Cargando…

Differential expansion of T peripheral helper cells in early rheumatoid arthritis and osteoarthritis synovium

OBJECTIVES: Programmed cell death protein 1 (PD-1)-expressing T cells are implicated in the pathogenesis of autoimmune inflammatory diseases such as rheumatoid arthritis. A subset of CXCR5(−) T cells, termed T peripheral helper (Tph) cells, which drive B cell differentiation, have been identified in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murray-Brown, William, Guo, Yanxia, Small, Annabelle, Lowe, Katie, Weedon, Helen, Smith, Malcolm D, Lester, Susan E, Proudman, Susanna M, Rao, Navin L, Hao, Ling-Yang, Nagpal, Sunil, Wechalekar, Mihir D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594577/ https://www.ncbi.nlm.nih.gov/pubmed/36270740 http://dx.doi.org/10.1136/rmdopen-2022-002563

Ejemplares similares

Features of the Synovium of Individuals at Risk of Developing Rheumatoid Arthritis: Implications for Understanding Preclinical Rheumatoid Arthritis
por: de Hair, MJH, et al.
Publicado: (2014)

Tocilizumab decreases T cells but not macrophages in the synovium of patients with rheumatoid arthritis while it increases the levels of serum interleukin-6 and RANKL
por: Chatzidionysiou, Katerina, et al.
Publicado: (2021)

Th1 is the predominant helper T cell subset that produces GM-CSF in the joint of rheumatoid arthritis
por: Yamada, Hisakata, et al.
Publicado: (2017)

Transcriptomic profiling of programmed cell death 1 (PD-1) expressing T cells in early rheumatoid arthritis identifies a decreased CD4 + PD-1 + signature post-treatment
por: Lowe, Katie, et al.
Publicado: (2023)

Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic
por: Druce, Katie L, et al.
Publicado: (2017)

Triple DMARD treatment in early rheumatoid arthritis modulates synovial T cell activation and plasmablast/plasma cell differentiation pathways
por: Walsh, Alice M., et al.
Publicado: (2017)

Genetic Liability to Rheumatoid Arthritis in Relation to Coronary Artery Disease and Stroke Risk
por: Yuan, Shuai, et al.
Publicado: (2022)

Trajectories of self-reported pain-related health outcomes and longitudinal effects on medication use in rheumatoid arthritis: a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
por: Pisaniello, Huai Leng, et al.
Publicado: (2023)

Mental health, fatigue and function are associated with increased risk of disease flare following TNF inhibitor tapering in patients with rheumatoid arthritis: an exploratory analysis of data from the Optimizing TNF Tapering in RA (OPTTIRA) trial
por: Bechman, Katie, et al.
Publicado: (2018)

Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials
por: Strand, Vibeke, et al.
Publicado: (2017)

Effects of exercise and physical activity promotion: meta-analysis informing the 2018 EULAR recommendations for physical activity in people with rheumatoid arthritis, spondyloarthritis and hip/knee osteoarthritis
por: Rausch Osthoff, Anne-Kathrin, et al.
Publicado: (2018)

Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

‘Should we stop or continue conventional synthetic (including glucocorticoids) and targeted DMARDs before surgery in patients with inflammatory rheumatic diseases?’
por: Goodman, Susan M, et al.
Publicado: (2020)

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
por: Riley, Thomas R, et al.
Publicado: (2021)

The Impact of Inflammation on Metabolomic Profiles in Patients With Arthritis
por: Young, Stephen P, et al.
Publicado: (2013)

Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses
por: Saleem, Benazir, et al.
Publicado: (2022)

Symptom Complexes at the Earliest Phases of Rheumatoid Arthritis: A Synthesis of the Qualitative Literature
por: Stack, Rebecca J, et al.
Publicado: (2013)

Tibialis Posterior Tenosynovitis and Associated Pes Plano Valgus in Rheumatoid Arthritis: Electromyography, Multisegment Foot Kinematics, and Ultrasound Features
por: Barn, Ruth, et al.
Publicado: (2013)

Impact of intensive treatment and remission on health-related quality of life in early and established rheumatoid arthritis
por: Scott, I C, et al.
Publicado: (2016)

No Evidence of Association Between Anti–Tumor Necrosis Factor Treatment and Mortality in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register
por: Lunt, Mark, et al.
Publicado: (2010)

Predictors of perceived risk in first-degree relatives of patients with rheumatoid arthritis
por: Bunnewell, Sarah, et al.
Publicado: (2022)

CD4+ and B Lymphocyte Expression Quantitative Traits at Rheumatoid Arthritis Risk Loci in Patients With Untreated Early Arthritis: Implications for Causal Gene Identification
por: Thalayasingam, Nishanthi, et al.
Publicado: (2018)

Predictors of Change in Bodily Pain in Early Rheumatoid Arthritis: An Inception Cohort Study
por: McWilliams, Daniel F, et al.
Publicado: (2012)

Clinical joint inactivity predicts structural stability in patients with established rheumatoid arthritis
por: Gärtner, M, et al.
Publicado: (2016)

Mortality Trends in Patients With Early Rheumatoid Arthritis Over 20 Years: Results From the Norfolk Arthritis Register
por: Humphreys, J H, et al.
Publicado: (2014)

A Multicenter, Randomized, Placebo‐Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis
por: Kitas, George D., et al.
Publicado: (2019)

Clinical Utility of Random Anti–Tumor Necrosis Factor Drug–Level Testing and Measurement of Antidrug Antibodies on the Long‐Term Treatment Response in Rheumatoid Arthritis
por: Jani, Meghna, et al.
Publicado: (2015)

Replication of Association of the PTPRC Gene With Response to Anti–Tumor Necrosis Factor Therapy in a Large UK Cohort
por: Plant, Darren, et al.
Publicado: (2012)

Rituximab or a second anti–tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti–tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register
por: Soliman, Moetaza M, et al.
Publicado: (2012)

Performance of the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis in a geographically distant National Register-based cohort: an external validation
por: Ljung, Lotta, et al.
Publicado: (2018)

Evaluating quality of care in rheumatoid arthritis: the patient perspective
por: Mahmood, Sehrash, et al.
Publicado: (2017)

Development and validation of a methotrexate adherence assay
por: Bluett, James, et al.
Publicado: (2019)

Two Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis
por: Furst, D E, et al.
Publicado: (2015)

Frailty in rheumatoid arthritis and its relationship with disease activity, hospitalisation and mortality: a longitudinal analysis of the Scottish Early Rheumatoid Arthritis cohort and UK Biobank
por: Hanlon, Peter, et al.
Publicado: (2022)

Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study
por: Winthrop, Kevin L., et al.
Publicado: (2019)

Genome-Wide Association Study of Genetic Predictors of Anti–Tumor Necrosis Factor Treatment Efficacy in Rheumatoid Arthritis Identifies Associations with Polymorphisms at Seven Loci
por: Plant, Darren, et al.
Publicado: (2011)

Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis
por: Low, Audrey S. L., et al.
Publicado: (2016)

Smartphone‐Assisted Patient‐Initiated Care Versus Usual Care in Patients With Rheumatoid Arthritis and Low Disease Activity: A Randomized Controlled Trial
por: Seppen, Bart, et al.
Publicado: (2022)

Multiomics and Machine Learning Accurately Predict Clinical Response to Adalimumab and Etanercept Therapy in Patients With Rheumatoid Arthritis
por: Tao, Weiyang, et al.
Publicado: (2020)

Impact of Psychological Factors on Subjective Disease Activity Assessments in Patients With Severe Rheumatoid Arthritis
por: Cordingley, Lis, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_uuub5tf3poqulktpcjhbonql2k